Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


01.03.2021

1 AJR Am J Roentgenol
2 Am J Pathol
1 Ann Oncol
9 Ann Surg Oncol
8 BMC Cancer
2 BMJ
3 Breast Cancer
1 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
16 Breast Cancer Res Treat
2 Breast J
3 Cancer
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
3 Clin Breast Cancer
1 Clin Cancer Res
3 Eur J Cancer
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
3 J Clin Oncol
1 J Natl Cancer Inst
1 J Pathol
2 Oncogene
1 PLoS Biol
2 PLoS One
1 Proc Natl Acad Sci U S A
1 Radiology
2 Radiother Oncol
1 Science


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. NGUYEN DL, Liang A, Mullen LA, Oluyemi E, et al
    Diagnostic Mammography for Post-Lumpectomy Surveillance in Women with Breast Cancer: Annual Frequencies of Additional Imaging and Recurrent Cancer.
    AJR Am J Roentgenol. 2021 Feb 24. doi: 10.2214/AJR.20.25417.
    PubMed         Abstract available


    Am J Pathol

  2. BERNARD JJ, Wellberg EA
    The tumor promotional role of adipocytes in the breast cancer micro- and macro-environment.
    Am J Pathol. 2021 Feb 24. pii: S0002-9440(21)00069.
    PubMed         Abstract available

  3. MALHERBE K
    Tumor microenvironment and the role of artificial intelligence in breast cancer detection and prognosis.
    Am J Pathol. 2021 Feb 24. pii: S0002-9440(21)00051.
    PubMed         Abstract available


    Ann Oncol

  4. DU L, Yau C, Brown-Swigart L, Gould R, et al
    Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.
    Ann Oncol. 2021 Feb 19. pii: S0923-7534(21)00128.
    PubMed         Abstract available


    Ann Surg Oncol

  5. PALMER KELLY E, Hyer M, Paredes AZ, McGee J, et al
    Assessing Differences in Cancer Surgeon Approaches to Patient-Centered Decision-Making Using Vignette-Based Methodology.
    Ann Surg Oncol. 2020;27:2149-2156.
    PubMed         Abstract available

  6. WIBERG R, Andersson MN, Svensson J, Rosen A, et al
    Prophylactic Mastectomy: Postoperative Skin Flap Thickness Evaluated by MRT, Ultrasound and Clinical Examination.
    Ann Surg Oncol. 2020;27:2221-2228.
    PubMed         Abstract available

  7. KLASSEN AF, Dominici L, Fuzesi S, Cano SJ, et al
    Development and Validation of the BREAST-Q Breast-Conserving Therapy Module.
    Ann Surg Oncol. 2020;27:2238-2247.
    PubMed         Abstract available

  8. HUDSON L, Gower N, Lenarcic S, Trufan SJ, et al
    Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.
    Ann Surg Oncol. 2020;27:2248-2254.
    PubMed         Abstract available

  9. KAIDAR-PERSON O, Cardoso MJ
    ASO Author Reflections: Residual Breast Tissue After Skin- and Nipple-Sparing Mastectomies: A Matter of Concern or a Point for Improvement/Action?
    Ann Surg Oncol. 2020;27:2297-2298.
    PubMed        

  10. KAIDAR-PERSON O, Boersma LJ, Poortmans P, Sklair-Levy M, et al
    Residual Glandular Breast Tissue After Mastectomy: A Systematic Review.
    Ann Surg Oncol. 2020;27:2288-2296.
    PubMed         Abstract available

  11. JONCZYK MM, Fisher CS, Babbitt R, Paulus JK, et al
    Surgical Predictive Model for Breast Cancer Patients Assessing Acute Postoperative Complications: The Breast Cancer Surgery Risk Calculator.
    Ann Surg Oncol. 2021 Feb 22. pii: 10.1245/s10434-021-09710.
    PubMed         Abstract available

  12. JONCZYK MM, Chatterjee A
    ASO Author Reflections: Predicting Complications in Breast Cancer Surgery Using the BCSRc.
    Ann Surg Oncol. 2021 Feb 26. pii: 10.1245/s10434-021-09763.
    PubMed        

  13. MA JC, Zhong XR, Luo T, Xiang ZZ, et al
    Correction to: The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype.
    Ann Surg Oncol. 2021 Feb 26. pii: 10.1245/s10434-021-09771.
    PubMed        


    BMC Cancer

  14. PU Q, Lv YR, Dong K, Geng WW, et al
    Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells.
    BMC Cancer. 2020;20:583.
    PubMed         Abstract available

  15. ZHAO F, Hao Z, Zhong Y, Xu Y, et al
    Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation.
    BMC Cancer. 2021;21:194.
    PubMed         Abstract available

  16. MATSON DR, Denu RA, Zasadil LM, Burkard ME, et al
    High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.
    BMC Cancer. 2021;21:186.
    PubMed         Abstract available

  17. TSUJI K, Matsuoka YJ, Ochi E
    High-intensity interval training in breast cancer survivors: a systematic review.
    BMC Cancer. 2021;21:184.
    PubMed         Abstract available

  18. BERGER K, Rhost S, Rafnsdottir S, Hughes E, et al
    Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
    BMC Cancer. 2021;21:185.
    PubMed         Abstract available

  19. GWYNNE WD, Shakeel MS, Girgis-Gabardo A, Kim KH, et al
    Antagonists of the serotonin receptor 5A target human breast tumor initiating cells.
    BMC Cancer. 2020;20:724.
    PubMed         Abstract available

  20. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed         Abstract available

  21. YU L, Shi Q, Jin Y, Liu Z, et al
    Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.
    BMC Cancer. 2021;21:195.
    PubMed         Abstract available


    BMJ

  22. MITTRA I, Mishra GA, Dikshit RP, Gupta S, et al
    Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai.
    BMJ. 2021;372:n256.
    PubMed         Abstract available

  23. MN W, L J, Jw H, Ks R, et al
    Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation.
    BMJ. 2021;372:n214.
    PubMed         Abstract available


    Breast Cancer

  24. KURODA H, Jamiyan T, Yamaguchi R, Kakumoto A, et al
    Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer.
    Breast Cancer. 2021 Feb 25. pii: 10.1007/s12282-021-01227.
    PubMed         Abstract available

  25. KUREBAYASHI J, Shiba E, Toyama T, Matsumoto H, et al
    A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-respons
    Breast Cancer. 2021 Feb 27. pii: 10.1007/s12282-020-01205.
    PubMed         Abstract available

  26. KAWATE T, Yoshida A, Sugae S, Asaga S, et al
    Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society.
    Breast Cancer. 2021 Feb 20. pii: 10.1007/s12282-020-01214.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  27. FLEISHER B, Lezeau J, Werkman C, Jacobs B, et al
    In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
    Breast Cancer (Dove Med Press). 2021;13:87-105.
    PubMed         Abstract available


    Breast Cancer Res

  28. AINE M, Boyaci C, Hartman J, Hakkinen J, et al
    Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly.
    Breast Cancer Res. 2021;23:28.
    PubMed        


    Breast Cancer Res Treat

  29. SUELMANN BBM, van Dooijeweert C, van der Wall E, Linn S, et al
    Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile.
    Breast Cancer Res Treat. 2021 Feb 26. pii: 10.1007/s10549-021-06130.
    PubMed         Abstract available

  30. TARANTINO P, Curigliano G
    Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06150.
    PubMed        

  31. LIU J, Li Y, Li Q, Liang D, et al
    Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06128.
    PubMed         Abstract available

  32. WANG YF, Wang XJ, Lu Z, Liu SR, et al
    Overexpression of Stat3 increases circulating cfDNA in breast cancer.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06142.
    PubMed         Abstract available

  33. LANAHAN CR, Kelly BN, Gadd MA, Specht MC, et al
    Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06106.
    PubMed         Abstract available

  34. CHANDRIKA M, Chua PJ, Muniasamy U, Huang RYJ, et al
    Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
    Breast Cancer Res Treat. 2021 Feb 24. pii: 10.1007/s10549-021-06123.
    PubMed         Abstract available

  35. PRUITT SL, Zhu H, Heitjan DF, Rahimi A, et al
    Survival of women diagnosed with breast cancer and who have survived a previous cancer.
    Breast Cancer Res Treat. 2021 Feb 23. pii: 10.1007/s10549-021-06122.
    PubMed         Abstract available

  36. VALLA M, Opdahl S, Ytterhus B, Bofin AM, et al
    DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06138.
    PubMed         Abstract available

  37. TANG M, Schaffer AL, Kiely BE, Daniels B, et al
    Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06135.
    PubMed         Abstract available

  38. GUHA R, Yue B, Dong J, Banerjee A, et al
    Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06120.
    PubMed         Abstract available

  39. TESCH ME, Chia SK, Simmons CE, LeVasseur N, et al
    Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
    Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06110.
    PubMed         Abstract available

  40. DUARTE C, Salazar A, Strasser-Weippl K, de Vries E, et al
    Breast cancer in Colombia: a growing challenge for the healthcare system.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-020-06091.
    PubMed         Abstract available

  41. MAN V, Kwong A
    Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06118.
    PubMed         Abstract available

  42. BRUNELLE CL, Barrio AV, Taghian AG
    Letter to editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements".
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06139.
    PubMed        

  43. JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
    Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.
    Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06113.
    PubMed         Abstract available

  44. WARE AW, Harris JJ, Slatter TL, Cunliffe HE, et al
    The epithelial sodium channel has a role in breast cancer cell proliferation.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06133.
    PubMed         Abstract available


    Breast J

  45. MEYER HJ, Wienke A, Surov A
    Diffusion weighted imaging to predict nodal status in breast cancer: A systematic review and meta-analysis.
    Breast J. 2021 Feb 21. doi: 10.1111/tbj.14200.
    PubMed        

  46. FILIZOGLU N, Ones T, Kesim S, Ozguven S, et al
    Paraneoplastic cerebellar degeneration: Initial presentation of occult breast cancer.
    Breast J. 2021 Feb 21. doi: 10.1111/tbj.14203.
    PubMed        


    Cancer

  47. NYANTE SJ, Benefield TS, Kuzmiak CM, Earnhardt K, et al
    Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures.
    Cancer. 2021 Feb 26. doi: 10.1002/cncr.33460.
    PubMed         Abstract available

  48. EMERSON MA, Achacoso NS, Benefield HC, Troester MA, et al
    Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33423.
    PubMed         Abstract available

  49. MUKAMA T, Kharazmi E, Sundquist K, Sundquist J, et al
    Risk-adapted starting age of breast cancer screening in women with a family history of ovarian or other cancers: A nationwide cohort study.
    Cancer. 2021 Feb 23. doi: 10.1002/cncr.33456.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  50. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
    Beta-blockers use and risk of breast cancer in women with hypertension.
    Cancer Epidemiol Biomarkers Prev. 2021 Feb 22. pii: 1055-9965.EPI-20-1599.
    PubMed         Abstract available

  51. AHERN TP, Sprague BL, Farina NH, Tsai E, et al
    Lifestyle, behavioral, and dietary risk factors in relation to mammographic breast density in women at high risk for breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2021 Feb 22. pii: 1055-9965.EPI-20-1567.
    PubMed         Abstract available


    Cancer Lett

  52. PHAM K, Huynh D, Le L, Delitto D, et al
    E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1.
    Cancer Lett. 2020;491:132-145.
    PubMed         Abstract available


    Clin Breast Cancer

  53. WU J, Zhou Z
    MicroRNA-432 Acts as a Prognostic Biomarker and an Inhibitor of Cell Proliferation, Migration, and Invasion in Breast Cancer.
    Clin Breast Cancer. 2021 Jan 23. pii: S1526-8209(21)00025.
    PubMed         Abstract available

  54. ANOOP TM, Joseph P R, Pn M, Kp P, et al
    Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents--An Observational Clinical Study.
    Clin Breast Cancer. 2021 Jan 23. pii: S1526-8209(21)00021.
    PubMed         Abstract available

  55. AGGARWAL A, Adepoju B, Yacur M, Maron D, et al
    Gender Disparity in Breast Cancer: A Veteran Population-Based Comparison.
    Clin Breast Cancer. 2021 Jan 26. pii: S1526-8209(21)00026.
    PubMed         Abstract available


    Clin Cancer Res

  56. PASCUAL T, Fernandez-Martinez A, Tanioka M, Dieci MV, et al
    Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy.
    Clin Cancer Res. 2021 Feb 25. pii: 1078-0432.CCR-20-4102.
    PubMed         Abstract available


    Eur J Cancer

  57. HUBEL K, Kron F, Lux MP
    Biosimilars in oncology: Effects on economy and therapeutic innovations.
    Eur J Cancer. 2020;139:10-19.
    PubMed         Abstract available

  58. GILLIS RD, Botteri E, Chang A, Ziegler AI, et al
    Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
    Eur J Cancer. 2021;147:106-116.
    PubMed         Abstract available

  59. JIANG M, Li CL, Luo XM, Chuan ZR, et al
    Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Eur J Cancer. 2021;147:95-105.
    PubMed         Abstract available


    Int J Cancer

  60. BELTJENS F, Molly D, Bertaut A, Richard C, et al
    ER-/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33539.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  61. WANG B, Huang X, Liang H, Yang H, et al
    PLK1 inhibition sensitizes breast cancer cells to radiation via suppressing autophagy.
    Int J Radiat Oncol Biol Phys. 2021 Feb 20. pii: S0360-3016(21)00203.
    PubMed         Abstract available


    J Clin Oncol

  62. WHELAN T, Levine M, Sussman J
    Hypofractionated Breast Irradiation: What's Next?
    J Clin Oncol. 2020;38:3245-3247.
    PubMed        

  63. HASHIMOTO K, Shimomura A
    Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer.
    J Clin Oncol. 2021 Feb 25:JCO2003215. doi: 10.1200/JCO.20.03215.
    PubMed        

  64. MODI S, Park H, Murthy RK, Iwata H, et al
    Reply to T.J.A. Dekker.
    J Clin Oncol. 2020;38:3351-3352.
    PubMed        


    J Natl Cancer Inst

  65. LOHMANN AE, Soldera SV, Pimentel I, Ribnikar D, et al
    Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
    J Natl Cancer Inst. 2021 Feb 23. pii: 6147022. doi: 10.1093.
    PubMed         Abstract available


    J Pathol

  66. WANG Y, Pan X, Li Y, Wang R, et al
    CUL4B renders breast cancer cells tamoxifen resistant via miR-32-5p/ER-alpha36 axis.
    J Pathol. 2021 Feb 27. doi: 10.1002/path.5657.
    PubMed         Abstract available


    Oncogene

  67. WU R, Li K, Yuan M, Luo KQ, et al
    Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells.
    Oncogene. 2021 Feb 24. pii: 10.1038/s41388-021-01691.
    PubMed         Abstract available

  68. GUAN X, Deng H, Choi UL, Li Z, et al
    EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis.
    Oncogene. 2020;39:7127-7141.
    PubMed         Abstract available


    PLoS Biol

  69. NIU M, He Y, Xu J, Ding L, et al
    Noncanonical TGF-beta signaling leads to FBXO3-mediated degradation of DeltaNp63alpha promoting breast cancer metastasis and poor clinical prognosis.
    PLoS Biol. 2021;19:e3001113.
    PubMed         Abstract available


    PLoS One

  70. NAFIE E, Lolarga J, Lam B, Guo J, et al
    Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1.
    PLoS One. 2021;16:e0247652.
    PubMed         Abstract available

  71. WANANDI SI, Limanto A, Yunita E, Syahrani RA, et al
    Correction: In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells.
    PLoS One. 2021;16:e0247694.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  72. ZHANG Y, Xie X, Yeganeh PN, Lee DJ, et al
    Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


    Radiology

  73. KWON MR, Choi JS, Won H, Ko EY, et al
    Breast Cancer Screening with Abbreviated Breast MRI: 3-year Outcome Analysis.
    Radiology. 2021 Feb 23:202927. doi: 10.1148/radiol.2021202927.
    PubMed         Abstract available


    Radiother Oncol

  74. MOUAWAD M, Lailey O, Poulsen P, O'Neil M, et al
    Intrafraction motion monitoring to determine PTV margins in early stage breast cancer patients receiving neoadjuvant partial breast SABR.
    Radiother Oncol. 2021 Feb 23. pii: S0167-8140(21)06084.
    PubMed         Abstract available

  75. VAN HULLE H, Desaunois E, Vakaet V, Paelinck L, et al
    Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: comparison with sequential boost in a randomized trial.
    Radiother Oncol. 2021 Feb 19. pii: S0167-8140(21)06070.
    PubMed         Abstract available


    Science

  76. ALON S, Goodwin DR, Sinha A, Wassie AT, et al
    Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems.
    Science. 2021;371.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: